Through the attached press release we are very happy to announce the agreement between BioMarin and Prosensa on the intended public offer for 100% of Prosensa’s outstanding stock. The total deal size is around $ 840 million of which $ 680 million is in cash. LSP was the lead investor in the series A round and still is the largest shareholder in Prosensa. We believe the Prosensa/Biomarin transaction is another illustration of the potential of science developed in The Netherlands, one of the core focus areas, together with Belgium and the German speaking countries, where LSP executes its long standing investment strategy.
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over USD 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit lspvc.com.
Prosensa N.V. is a biotechnology company based in Leiden, The Netherlands, which discovers and develops RNA-modulating therapeutics for the treatment of genetic disorders. The primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including DMD, myotonic dystrophy and Huntington’s disease. Prosensa’s lead compound for DMD, is drisapersen. Its seven follow-on programs for other DMD genotypes are currently in various stages of development from preclinical through Phase 2. In addition, the Company has preclinical products in development for Huntington’s disease and myotonic dystrophy. The Company has 85 employees.
For more information, please contact:
Martijn Kleijwegt, Managing Partner LSP
Tel: +31 20 664 5500